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Chemotherapy is one of the modality therapies given to breast cancer patients to inhibit 
cancer cell metastases. The side effects of chemotherapy can suppress the hematopoietic 
system in the bone marrow and progressively affect the patient's prognosis. The aim of 
study was to analyze routine blood profiles as supporting data in developing nursing care 
for breast cancer patients undergoing chemotherapy at the RSU. Dr. Wahidin 
Sudirohusodo Makassar, Indonesia, from June to September 2018. This research was a 
descriptive research with descriptive survey method. This research was conducted at the 
RSU Surgical Polyclinic. Dr. Wahidin Sudirohusodo. The sampling technique used was 
Non-Probability Sampling a purposive sampling method. The participants of this study 
were patients with breast cancer who undergo chemotherapy treatment with a number of 
samples that meet the inclusion criteria as many as 32 people. of the 17 routine blood 
components which were assessed as one of the investigations in 32 patients were found to 
be 4 abnormal components, red blood cells mean ± SD (3.99 10^6/ uL ± 0.51), hemoglobin 
mean ± SD (11.18 gr/dl ± 1.09), hematocrit mean ± SD (34.96% ± 3.96), and mean ± SD 
monocyte (15,043 10^3/uL ± 8.95). due to metastasis and side effects of chemotherapy 
treatment decrease red blood cells, hemoglobin, hematocrit, and increase in specific 
immune response through increase of monocytes indicator that performing phagocytosis.. 
 
Background 
 
 WHO data in 2013 showed that there were more than 508,000 women predicting breast cancer 
mortality worldwide in 2011. GLOBOCAN data in 2008, although breast cancer was a disease in developed 
countries, it turned out that 50% of cases and 58% of deaths occurred in developing countries[1].  
In Indonesia, the prevalence of cancer is also quite high. Based on data from the Basic Health 
Research (Riskesdas) in 2013, the prevalence of tumors/ cancer in Indonesia is 1.4 per 1000 population, or 
about 330,000 people[2] 
Data on Hospital Information Systems (SIRS) in 2013 explained that the number of inpatients with 
carcinoma in all hospitals in Indonesia was 1.4 per 1000 population and constituted 5.7% of the causes of 
death from all diseases. Mammary carcinoma was recorded as the highest type of cancer in inpatients and 
outpatients care in all hospitals in Indonesia with a total of 12,014 patients or 28.7% followed by cervical 
cancer as many as 5,786 cases or 11.78%[3]. 
At present, the decision of the determination of therapy tends to lead to the molecular classification of 
breast cancer. Women diagnosed with breast or ovarian cancer will face with aggressive chemotherapy 
including treatment with drugs combination. This treatment can have an effect on quality of life or have side 
effects. Chemotherapy can cause nausea, vomiting, hair loss, cognitive dysfunction, fatigue, changes in 
sexual function, and decreased quality of life. The impact on fertility, premature menopause, and bone 
healthy is also another effect from chemotherapy of breast cancer patients. 
Chemotherapy has beneficial effects on the prognosis of breast cancer, but on the other hand, it is 
feared could lead to side effects. Side effects of chemotherapy are bone marrow depression, diarrhea, hair 
loss, nausea, and other health problems. Anemia as a pathology response with neoadjuvand therapy and 
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chemotherapy can affect the survival of the patient [4].   
If these problems are not treated, they will cause further problems, like the disturbance of nutritional 
balance and will ultimately lead to a decrease in quality of life in cancer patients. Those are what causes the 
tendency of breast cancer sufferers to refuse chemotherapy or the chemotherapy cycle that has been 
scheduled to be interrupted before the therapy ends.  
Examined the effect of chemotherapy on bone marrow in 274 gynecological cancers and 503 breast 
cancers[5].  Side effects on hematopoietic cells occur in 28.8% of patients and begin to occur at any time 
when the cycle of chemotherapy is given and the tendency to increase at the end of the cycle. The amount of 
erythrocyte, hemoglobin, neutrophil and platelet production will decrease and will reduce the ability of 
phagocytosis to cancer cells so that it worsens the prognosis. Hemoglobin, neutrophils and platelets can be 
used as a measure of hematopoietic cell conditions. Examined the side effects of cisplatin chemotherapy as 
a part of chemotherapy drugs and hematopoietic side effects based on hemoglobin, leukocytes and 
platelets[6].  These side effects begin to occur after the first cycle and were significant after the next cycle. 
So, the routine blood images can be a source of prognostic information and supporting data in nursing 
assessment that are important and can to predict clinical outcomes development of cancer metastases, 
including in developing nursing care.  
The aim of nursing care is to identify client problems. The nursing process is one of the main 
approaches in providing nursing care which is a process of decision-making and problem-solving. After the 
application of the nursing process, nurses are required to have knowledge of concepts and theories as the 
basis for interpreting the data obtained. 
 
Methods 
 
This study used a descriptive analysis method in outpatient care Installation of RSU. Dr. Wahidin 
Sudirohusodo. Data processing included patient characteristics and routine blood analysis performed on 32 
patients with ages ranging from 32 years to 68 years. The sample was a patient with a diagnosis of breast 
cancer who underwent chemotherapy at the RSU. Dr. Wahidin Sudirohusodo, from July to October 2018. 
Blood samples were taken at the polyclinic laboratory using EDTA (ethylenediaminetetraacetic acid). The 
sampling technique used was non-probability sampling with a purposive sampling method in breast 
cancer patients who underwent chemotherapy treatment with the number of samples that met the 
inclusion criteria as many as 32 people.  
 
Results 
 
This research was carried out from July to October 2018. The implementation of this research was in 
Outpatient Care Installation at Wahidin Sudirohusodo Hospital. The number of samples in this study was 32 
people. The distribution of patient characteristics can be seen in the following table.  
 
Table 1. Demographic Characteristics of Patients with  Breast Cancer  with Chemotherapy 
                           Variable                                            N 
Age (years) 
(mean ± SD) 
Min-max 
 
Education Level 
Elementary 
Junior high School 
Senior High School 
College 
Not School 
 
Terms of Suffering(years) 
(mean ± SD) 
Min - Max 
1-3 years 
4 - 6 years 
 
Status 
Married 
Divorced 
Not Married 
 
46.84 ± 9176 
32 - 68 
 
 
4 (12.5%) 
10 (31.3%) 
13 (40.6%) 
3 (9.4%) 
2 (6.3%) 
 
 
1.22 ± 0.42 
1-7 
25 
7 
 
 
28 (87.5%) 
1 (3.1%) 
3 (9.4%) 
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A total of 32 breast cancer patients who underwent chemotherapy, an average age of 46 years were 
still in the productive age range, based on the highest level of education graduated from high school (40.6 
%), while the average long-suffering 1:22 year and the most long-suffering 1-3 years (78%) and on the 
basis of marital status on average most patients were married (87.5%). 
 
Table 2. Distribution frequency of Routine Blood in  Breast Cancer patients with Chemotherapy 
             Mean SD Reference 
Values 
Unit 
WBC 7714 5.4069 4:00 - 10.0 10^3 / uL 
RBC 3.9957 0.51528 4:00 - 6:00  10^6/ uL 
HGB 11,186 1.0987 12.0 - 16.0  gr / dL 
HCT 34.96 3,491 37.0 – 48.0                                     % 
MCV 87.96 6077 80.0 - 97.0  fL 
MCH 28.21 2,347 26.5 - 33.5  pg 
MCHC 41.96 52.738 31.5 - 35.0  gr / dL 
PLT 346.43 130,183 150 - 400  10^3/ uL 
RDW-CV 15,543 2.6872 10.0 - 15.0   
PDW 9,796 1.2808 10.0 - 18.0  fL 
MPV 9.35 0.6489 6.50 - 11.0  fL 
PCT 0.3411 1,292 0.15 - 0.50  % 
NUET 49.5 17.8409 52.0 - 75.0  % 
LYMPH 31,821 11,0087 20.0 - 40.0  % 
MONO 15,043 8,9535 2.00 - 8.00  10^3 / uL 
EO 3,086 3.4497 1.00 - 3.00  10^3 / uL 
BASO 0.7339 0.31974 0.00 - 0.10  1 ^3 / uL 
 
From the data component in Table 2. routine blood tests found in breast cancer patients with 
chemotherapy treatment, abnormalities can be seen from the decrease in the average value on RBC levels 
(3.9957 ) 10^6 /uL; Hb level mean (11,186) gr/dL; hematocrit (34.96) %; and an increase in monocyte 
levels (15,043) 10^3 /uL. 
 
Discussion 
 
Chemotherapy with a given regimen that belongs to the cytostatic group can cause a decrease in 
hematopoietic cells, especially hemoglobin[5]. Previous studies have identified anemia as an independent 
prognostic factor, which has a detrimental effect on survival in several types of cancer including breast 
cancer[7]. According to Zhu W (2015), the incidence of anemia before chemotherapy was associated with 
a poor pathological response to neoadjuvant therapy which has an impact on survival in breast cancer 
patients[4]. 
 This study found that erythrocytes (3,9957) 10^6 /uL were less than normal which had an impact 
on low Hb levels with the mean (11,186) gr/dL indicating anemia. In another study, it was suggested that 
low Hb levels (13 gr/dL) in breast cancer were due to the effects of neoadjuvand treatment through anti-
proliferation inhibition[8]. 
 One type of cytostatic drug Cisplatin causes damage to DNA through the intrastrand cross-linked 
DNA due tocontribution ROS, cytrocrom-c, JNK, p38MAPK, caspase[9]. This causes a decrease in 
hemoglobin and anemia due to the occurrence of death cell or development disorders of bone marrow 
cell, especially pathway of megakaryocyte erythrocyte progenitor followed by impaired erythroblast 
progenitor production, which causes a decrease in the number of reticulocytes and erythrocytes [10] 
 In this study, Table 2 showed increase levels of monocytes is high enough with mean (10^3/uL), 
this could be caused by factors carcinogenesis and metastasis of systemic inflammation as a side effect of 
cytostatic drugs. Monocytes are reticuloendothelial system, that circulating but non-phagocytes, then after 
a few hours in the cells develop into tissue macrophages.  
 There are many data that indicate the important role of the local immune response in 
carcinogenesis, but the systemic inflammatory response also seems to take part in this process[7], besides 
the concentration of C-reactive protein (CRP) and several cytokines (interleukin (IL) -1ra, IL-6, IL-7, IL-8, 
IL-9, IL-12, interferon γ, interferon γ-protein induced byIl-10, monocyte chemotactic protein 1, 
inflammatory macrophages of protein 1β and platelet growth factors, and hypoalbuminemia, indirectly 
reflect the impact of immune system activity [10]. 
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 Shibutani et al (2017).,  suggested that peripheral monocyte counts were positively related to the 
density of macrophages in tumors, and their correlated increase in value did not benefit the 
prognosis[11]. There is a hypothesis that shows that Cancer cells produce chemokines (such as CCL2) 
which recruit monocytes from peripheral blood to tumors [12], and will activate parts of monocytes from 
bone marrow to peripheral blood. Because cytokines present in the micro cancer environment 
(stimulating factors of macrophage colonies, the transformation of growth factor-β (TGF-β), IL-6, and IL-
10), white blood cells differentiate into two macrophage phenotypes: antitumor M1 and procarcinogenic 
M2. The latter applies in the micro environment of tumors and produces vascular endothelial growth 
factor/angiogenic factors (VEGF) and tumor necrosis factor-α (TNF-α)) so they facilitate neoangiogenesis 
and matrix metalloproteinase in tumor cells.  
 Assessment and diagnosis in the nursing process is an input (stressor) based on the results of 
interviews, physical examinations and laboratory data. Problems arise if the adaptation system cannot 
respond and solve problems that caused by changes in the environment in an effort to maintain system 
integrity. 
 From this study expected that nurses who go through the critical-thinking process must be able to 
analyze data starting from the system level, organs, cells, and molecules/genes. Immunity indicator as a 
reference for nurses to be able to formulate problems accurately. Problems found can be accounted for 
scientifically. The final result of this stage was the identification of nursing problems, which were grouped 
into: (1) physical (biological); (2) psychological; (3) social; (4) spiritual. 
 
 
Conclusion and Suggestion 
The conclusion of this study was there were a decrease in erythrocytes, hemoglobin, hematocrit, 
and increase of monocytes in breast cancer patients undergoing chemotherapy treatment at the RSUP 
surgical polyclinic, Dr. Wahidin Sudirohusodo.  
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